Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Iclepertin and Donepezil in Healthy Subjects
NCT03905096Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2019
- Primary completion
- Aug 2019
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of iclepertin in Alzheimer's disease (AD) and schizophrenia (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve From 0 Extrapolated to Infinity and Maximum Measured Concentration. Started Apr 2019; status: completed.
02
Drugs
iclepertin
03
Conditions
Alzheimer's disease (AD)schizophrenia
Beyond the preview
Go deeper on NCT03905096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03905096.